1887
Rapid communication Open Access
Like 0

Abstract

In December 2018, a ceftazidime-avibactam (CAZ-AVI)-resistant KPC-2-producing strain was isolated in Finland. CAZ-AVI resistance was observed 34 days after CAZ-AVI treatment in a trauma patient transferred from a hospital in Greece who had been colonised with bla-producing ST39, and later developed a bloodstream infection. The CAZ-AVI-resistant strain contained a novel 15 amino acid insertion in the KPC-2 protein causing structural changes proximal to the KPC-2 active site.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.19.1900256
2019-05-09
2024-12-27
/content/10.2807/1560-7917.ES.2019.24.19.1900256
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/19/eurosurv-24-19-1.html?itemId=/content/10.2807/1560-7917.ES.2019.24.19.1900256&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae – 12 June 2018. Stockholm; ECDC; 2018. Available from: https://ecdc.europa.eu/en/publications-data/rapid-risk-assessment-emergence-resistance-ceftazidime-avibactam-carbapenem
  2. Julkari. Ohje moniresistenttien mikrobien tartunnantorjunnasta [Help with anti-microbial infection control]. Finland: Julkari; 2017. Finnish. Available from: http://urn.fi/URN:ISBN:978-952-302-943-9.
  3. van Beek J, Räisänen K, Broas M, Kauranen J, Kähkölä A, Laine J, et al. Tracing local and regional clusters of carbapenemase-producing Klebsiella pneumoniae ST512 with whole-genome sequencing, Finland, 2013-2018. Euro Surveill. 2019; (Forthcoming).
  4. Kluytmans-van den Bergh MF, Rossen JW, Bruijning-Verhagen PC, Bonten MJ, Friedrich AW, Vandenbroucke-Grauls CM, et al. Whole-Genome Multilocus Sequence Typing of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae. J Clin Microbiol. 2016;54(12):2919-27.  https://doi.org/10.1128/JCM.01648-16  PMID: 27629900 
  5. Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234(3):779-815.  https://doi.org/10.1006/jmbi.1993.1626  PMID: 8254673 
  6. Schrödinger LLC. PyMOL by Schrödinger. Molecular Graphics System. Version 2.1.0. Available from: https://pymol.org
  7. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017;61(3):e02097-16.  https://doi.org/10.1128/AAC.02097-16  PMID: 28031201 
  8. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases. Antimicrob Agents Chemother. 2017;61(5):e02534-16.  https://doi.org/10.1128/AAC.02534-16  PMID: 28223379 
  9. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018;73(6):1525-9.  https://doi.org/10.1093/jac/dky082  PMID: 29566151 
  10. Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, Mcconville TH, et al. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates. 2018;62(3):e02101-17.
  11. Both A, Büttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother. 2017;72(9):2483-8.  https://doi.org/10.1093/jac/dkx179  PMID: 28637339 
  12. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. Växjö: EUCAST; 2018. Available from: http://www.eucast.org.
/content/10.2807/1560-7917.ES.2019.24.19.1900256
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error